Search research articles
Contact Us
Filters
Showing results (51-60 of 74) with videos related to
Page
of 8
Sort By:
Journal of Neural Transmission. Parkinson'S Disease and Dementia Section
|
January 1, 1990
Neuroleptic-induced catalepsy as a model of Parkinson's disease. I. Effect of dopaminergic agents
P J Elliott, S P Close, D M Walsh, et al.
Clinical Chemistry
|
May 5, 2000
Proteasome inhibition measurements: clinical application
E S Lightcap, T A McCormack, C S Pien, et al.
Journal of Autoimmunity
|
April 11, 2000
Treatment of established relapsing experimental autoimmune encephalomyelitis with the proteasome inhibitor PS-519
C L Vanderlugt, S M Rahbe, P J Elliott, et al.
Stroke
|
December 12, 2001
Postischemic (6-Hour) treatment with recombinant human tissue plasminogen activator and proteasome inhibitor PS-519 reduces infarction in a rat model of embolic focal cerebral ischemia
L Zhang, Z G Zhang, R L Zhang, et al.
Cancer Research
|
April 18, 2001
The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells
T Hideshima, P Richardson, D Chauhan, et al.
Nature
|
December 22, 1983
Role of endogenous substance P in stress-induced activation of mesocortical dopamine neurones
M J Bannon, P J Elliott, J E Alpert, et al.
Neuropharmacology
|
September 1, 1994
Increased sensitivity to the antinociceptive activity of (+/-)-baclofen in an animal model of chronic neuropathic, but not chronic inflammatory hyperalgesia
G D Smith, S M Harrison, P J Birch, et al.
Cancer Research
|
April 28, 2001
Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition
J C Cusack, R Liu, M Houston, et al.
Experimental Neurology
|
October 1, 1996
Unlocking the blood-brain barrier: a role for RMP-7 in brain tumor therapy
P J Elliott, N J Hayward, M R Huff, et al.
American Journal of Hematology
|
December 12, 1997
Telomere length in myelodysplastic syndromes
J Boultwood, C Fidler, R Kusec, et al.
Page
of 8
Search research articles
Search
Showing results (51-60 of 74) with videos related to
Sort By:
Page
of 8
Journal of Neural Transmission. Parkinson'S Disease and Dementia Section
|
January 1, 1990
Neuroleptic-induced catalepsy as a model of Parkinson's disease. I. Effect of dopaminergic agents
P J Elliott, S P Close, D M Walsh, et al.
Clinical Chemistry
|
May 5, 2000
Proteasome inhibition measurements: clinical application
E S Lightcap, T A McCormack, C S Pien, et al.
Journal of Autoimmunity
|
April 11, 2000
Treatment of established relapsing experimental autoimmune encephalomyelitis with the proteasome inhibitor PS-519
C L Vanderlugt, S M Rahbe, P J Elliott, et al.
Stroke
|
December 12, 2001
Postischemic (6-Hour) treatment with recombinant human tissue plasminogen activator and proteasome inhibitor PS-519 reduces infarction in a rat model of embolic focal cerebral ischemia
L Zhang, Z G Zhang, R L Zhang, et al.
Cancer Research
|
April 18, 2001
The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells
T Hideshima, P Richardson, D Chauhan, et al.
Nature
|
December 22, 1983
Role of endogenous substance P in stress-induced activation of mesocortical dopamine neurones
M J Bannon, P J Elliott, J E Alpert, et al.
Neuropharmacology
|
September 1, 1994
Increased sensitivity to the antinociceptive activity of (+/-)-baclofen in an animal model of chronic neuropathic, but not chronic inflammatory hyperalgesia
G D Smith, S M Harrison, P J Birch, et al.
Cancer Research
|
April 28, 2001
Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition
J C Cusack, R Liu, M Houston, et al.
Experimental Neurology
|
October 1, 1996
Unlocking the blood-brain barrier: a role for RMP-7 in brain tumor therapy
P J Elliott, N J Hayward, M R Huff, et al.
American Journal of Hematology
|
December 12, 1997
Telomere length in myelodysplastic syndromes
J Boultwood, C Fidler, R Kusec, et al.
Page
of 8